A phase 1/2a, dose-escalation, safety and preliminary efficacy study of oral therapeutic vaccine in subjects with cervical intraepithelial neoplasia 3

Young Chul Park, Yung Taek Ouh, Moon Hee Sung, Hong Gyu Park, Tae Jin Kim, Chi Heum Cho, Jong Sup Park, Jae Kwan Lee

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Objective: Persistent infection of HPV increases the chance of carcinoma in situ of cervix through stages of cervical intraepithelial neoplasia (CIN) 1, 2, and 3, and finally progresses into cervical cancer. We aimed to explore the safety and efficacy of BLS-M07 which is orally administered agent expressing human papillomavirus (HPV) 16 E7 antigen on the surface of Lactobacillus case in patients with CIN 3. Methods: Patients with CIN 3 were recruited in our clinical trial. Reid Colposcopic Index (RCI) grading and serum HPV16 E7 specific antibody production were used to evaluate efficacy of BLS-M07. In phase 1, BLS-M07 was administered orally, 5 times a week, on weeks 1, 2, 4, and 8 with dosages of 500 mg, 1,000 mg, and 1,500 mg. In phase 2a, patients were treated with 1,000 mg. The primary endpoints were the safety and the pathologic regression on colposcopic biopsy. Results: Nineteen patients were enrolled in the CIN 3 cohort. In phase 1, no patients experienced dose limiting toxicity. No grade 3 or 4 treatment-related adverse events or deaths were observed. At 16 weeks after treatment, RCI grading was improved and serum HPV16 E7 specific antibody production increased (p<0.05). Six of 8 (75%) patients with CIN 3 were cured in phase 2a. Conclusions: Oral immunization with BLS-M07 increases production of serum HPV16 E7 specific antibody which induces protective humoral immunity. The safety of this oral vaccine was proved and could be a competitive non-surgical therapeutic agent of CIN 3.

Original languageEnglish
Article numbere88
JournalJournal of gynecologic oncology
Volume30
Issue number6
DOIs
Publication statusPublished - 2019 Nov

Keywords

  • Cervical Intraepithelial Neoplasia
  • Papillomavirus E7 Proteins
  • Papillomavirus Vaccines

ASJC Scopus subject areas

  • Oncology
  • Obstetrics and Gynaecology

Fingerprint Dive into the research topics of 'A phase 1/2a, dose-escalation, safety and preliminary efficacy study of oral therapeutic vaccine in subjects with cervical intraepithelial neoplasia 3'. Together they form a unique fingerprint.

  • Cite this